Contributors:Tanner Marshall, MS, Marisa Pedron, Robyn Hughes, MScBMC, Elizabeth Nixon-Shapiro, MSMI, CMI
Adrenal hormone synthesis inhibitors or AHSIs are a group of medications which basically inhibit the synthesis of adrenocortical hormones, more specifically cortisol, which is a glucocorticoid hormone produced by the adrenal cortex.
Normally, the hypothalamus, which is located at the base of the brain, secretes corticotropin-releasing hormone, known as CRH, which stimulates the pituitary gland to secrete adrenocorticotropic hormone, known as ACTH.
ACTH, then, travels to the pair of adrenal glands, on top of each kidney, where it specifically targets cells in the adrenal cortex.
This causes the adrenocortical cells to take up cholesterol from the blood, and it also stimulates an enzyme called cholesterol desmolase inside these cells, which converts cholesterol to pregnenolone.
Then, another enzyme called 3 beta- hydroxysteroid dehydrogenase, (or 3 beta- HSD) turns some of this pregnenolone into progesterone.
17 alpha hydroxypregnenolone is then turned into 17 alpha hydroxyprogesterone by the enzyme 3 beta- hydroxysteroid dehydrogenase.
Then, all of the 17 alpha hydroxyprogesterone is turned into 11 deoxycortisol by the enzyme 21 hydroxylase.
11 deoxycortisol is finally turned into cortisol by the enzyme 11 beta-hydroxylase.
In times of stress, the body needs to have plenty of energy substrates around, so cortisol increases gluconeogenesis, which is the synthesis of new glucose molecules, proteolysis, which is the breakdown of protein and lipolysis, which is the breakdown of fat.
Cortisol also helps to maintain the blood pressure by increasing the sensitivity of peripheral blood vessels to catecholamines- epinephrine and norepinephrine, and this narrows the blood vessel lumen.
Cortisol helps to dampen the inflammatory and immune response by reducing the production and release of inflammatory mediators, like prostaglandins and interleukins, as well as inhibiting the proliferation of T-lymphocytes.
Finally, cortisol receptors are present in the brain, where their full effect is still actually unclear but might influence things like mood and memory.
Now, in Cushing’s syndrome, there’s increased cortisol levels over a long period of time.
This could be due to Cushing’s disease, which is caused by a benign pituitary adenoma that secretes too much ACTH.
Another cause is adrenocortical carcinomas, which overproduce cortisol.
Bones are also broken down which could lead to osteoporosis.
In those cells, the insulin activates lipoprotein lipase, which is an enzyme that helps those adipocytes accumulate more fat molecules.
The result is central obesity, which is fat build up in the abdomen, buffalo hump, which is fat build up between the shoulders, and moon facies which is fat build up in the face.
Alright, so, whatever the cause, the problem is high cortisol level.
If these medications fail, we can also destroy the adrenocortical cells with mitotane.
Let’s begin with Ketoconazole, which is an antifungal medication that is also used as the first-line treatment for Cushing’s syndrome.
It’s taken orally and it works by inhibiting several enzymes important in the synthesis of adrenal steroids.
Ultimately, this results in decreased synthesis of cortisol!
Other indications for ketoconazole include breast and prostate cancer; but it’s important to note that it can be also used to reduce androgenic symptoms, such as hirsutism, or excessive facial hair growth, and acne, in individuals with polycystic ovary syndrome (PCOS).
It’s also teratogenic so it should not be given during pregnancy.
Finally, it’s important to note that ketoconazole is a potent CYP3A4 inhibitor; therefore, concomitant use of ketoconazole and medications that are metabolized by this enzyme can lead to their decreased metabolism, increased blood levels, and eventual toxicity.
- "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
- "Rang and Dale's Pharmacology" Elsevier (2019)
- "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
- "The Treatment of Cushing's Disease" Endocrine Reviews (2015)
- "Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study" Endocrine Connections (2018)
- "Sex differences in ACTH pulsatility following metyrapone blockade in patients with major depression" Psychoneuroendocrinology (2007)
- "Medical management of Cushing’s disease: what is the future?" Pituitary (2012)